© 2022 MJH Life Sciences™ and HCPLive - Clinical news for connected physicians. All rights reserved.
June 28, 2021
Marc P. Bonaca, MD, MPH, of the University of Colorado School of Medicine, comments on the potential to personalize treatment with emerging therapies in the pipeline to better manage patients at high risk for cardiovascular disease in the future.
Unmet needs in the management of coronary artery disease and peripheral artery disease, and advice for working with patients and other healthcare professionals to optimize care for patients at high risk for cardiovascular disease.
June 21, 2021
Drs Marc P. Bonaca and Manesh R. Patel discuss the rationale for individualized treatment plans for patients with type 2 diabetes at high risk for cardiovascular disease.
Implications for treating patients at risk of cardiovascular disease with rivaroxaban plus aspirin based on the COMPASS and VOYAGER PAD clinical trials.
Daily Insulin Titration Results in Lower Fasting Glucose for Gestational Diabetes
Beti-Cel Gene Therapy for β-Thalassemia Receives FDA Approval
Long-Acting Insulin Analogues Reduce MACE Risk in Patients with T2D